In vitro and in vivo antibacterial activity of DRPM, a new carbapenem
|
Accession number;05A0663306
|
| Title;In vitro and in vivo antibacterial activity of DRPM, a new carbapenem |
| Author;
TSUJI MASAKATSU
(Toho Univ., School of Med.)
FURUYA NOBUHIKO
(Toho Univ., School of Med.)
MATSUMOTO TETSUYA
(Toho Univ., School of Med.)
ISHII YOSHIKAZU
(Toho Univ., School of Med.)
ONO AKIRA
(Toho Univ., School of Med.)
TATEDA KAZUHIRO
(Toho Univ., School of Med.)
MIYAZAKI SHUICHI
(Toho Univ., School of Med.)
YAMAGUCHI KEIZO
(Toho Univ., School of Med.)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.53;NO.Supplement 1;PAGE.1-16(2005)
|
| Figure&Table&Reference;FIG.3, TBL.9, REF.19 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We compared the in vitro and in vivo antibacterial activity of DRPM (formerly S-4661), a new 1.BETA.-methylcarbapenem, with that of imipenem, panipenem, merapenem, biapenem, cefpirome, ceftazidime, and cefotaxime. DRPM was highly active against methicillin-susceptible staphylococci, penicillin-resistant S. pneumoniae and members of the family Enterobacteriaceae such as Escherichia coli and Enterobacter cloacae, with a MIC at which 90% of tested strains were inhibited (MIC90) to 1.MU.g/mL or less. Against imipenem-, ceftazidime-, ciprofloxacin-, and gentamicin-resistant P. aeruginosa, DRPM was the most active among tested agents. The in vivo efficacy of DRPM against experimentally induced infection in mice caused by gram-positive and gram-negative bacteria, including penicillin-resistant Streptococcus pneumoniae and .BETA.-lactamase producing H. influenzae was similar to that of imipenem-eilastatin and meropenem-cilastatin. We conclude that DRPM is a promising new carbapenem for treating infections caused by gram-positive and negative bacteria, including penicillin-resistant S. pneumoniae and drug-resistant P. aeruginosa. (author abst.) |
|
|
|
Related Articles;
|
|
